Vor Bio, RemeGen announce Phase 3 study of telitacicept met primary endpoint

Vor Bio (VOR) announced that its collaborator, RemeGen (REGMF), achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjogren’s disease. “For decades, patients with primary Sjogren’s disease have faced limited treatments options, and telitacicept offers a potential option for these patients which targets the root cause of this devastating autoimmune disease. In an indication where therapeutic progress has been measured in incremental steps, the results from telitacicept suggest the potential for a best-in-disease profile and could set a new benchmark in the field,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. “By targeting both BAFF and APRIL, telitacicept addresses the upstream and downstream autoimmune signaling cascade, offering the possibility of truly modifying the disease instead of simply managing symptoms. This dual-target profile has also shown transformative potential in myasthenia gravis, our lead indication, highlighting telitacicept as a potential pipeline-in-a-product with broad applicability across autoimmune diseases. Sjogren’s represents a significant global expansion opportunity for Vor beyond myasthenia gravis, further extending the reach and impact of our portfolio.”